Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust recovery in the Hong Kong economy, with GDP growth of 3.5% in 2025 and a notable increase in retail sales, which rose by 5.5% year-on-year in January 2026 [25][27] - The residential property market in Hong Kong is showing signs of recovery, with the leading index rising by 8% year-on-year as of February 22, 2026, indicating a positive trend in housing prices [28][30] - The medical aesthetics sector, particularly the company "四环医药," is experiencing significant growth, with revenues exceeding 1.4 billion yuan and profits over 700 million yuan in 2025, reflecting a year-on-year growth rate of over 90% [43][44] Summary by Sections Government Work Report - The 2026 government work report emphasizes boosting consumption as a core strategy for expanding domestic demand, introducing measures to increase income for low-income groups and enhance consumer spending capacity [13][14] - New policies include a 100 billion yuan special fund to promote domestic demand and support for service consumption [13][16] Economic Recovery in Hong Kong - Hong Kong's economy is on a steady recovery path, with GDP growth of 3.5% in 2025 and a 3.8% increase in Q4, driven by both consumption and exports [26][27] - Retail sales are projected to reach approximately 410 billion HKD in 2026, marking an 8% year-on-year increase, with significant growth expected in jewelry, clothing, and cosmetics [27] Real Estate Market Trends - The residential property market is recovering, with the leading index reaching 149.41 points, an 8% increase year-on-year, and the private residential price index showing a 4.9% increase, marking eight consecutive months of growth [28][32] - The "cooling" measures in the property market have been fully implemented, reducing transaction costs and stimulating market liquidity [38][39] Medical Aesthetics Sector - The medical aesthetics division of "四环医药" is becoming a major revenue and profit driver, with a projected revenue of over 2.5 billion yuan in 2025, reflecting a growth rate exceeding 30% [43][44] - The company has a diverse product matrix, including successful products like "乐提葆" and "铂安润," which are contributing significantly to its revenue growth [48][49]

Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust recovery in the Hong Kong economy, with GDP growth of 3.5% in 2025 and a notable increase in retail sales, which rose by 5.5% year-on-year in January 2026 [25][27] - The residential property market in Hong Kong is showing signs of recovery, with the leading index rising by 8% year-on-year as of February 22, 2026, indicating a positive trend in housing prices [28][30] - The medical aesthetics sector, particularly the company "Four Ring Pharmaceutical," is experiencing significant growth, with revenues exceeding 1.4 billion yuan and profits surpassing 700 million yuan in 2025, reflecting a year-on-year growth rate of over 90% [43][44] Summary by Sections Government Work Report - The 2026 government work report emphasizes boosting consumption as a core strategy for expanding domestic demand, introducing measures to increase income for low-income groups and enhance consumer spending capacity [13][14] - New policies include a 1 billion yuan special fund to promote domestic demand and support for service consumption [13][16] Economic Recovery in Hong Kong - Hong Kong's economy is on a steady recovery path, with GDP growth of 3.5% in 2025 and a 3.8% increase in Q4, driven by both consumption and exports [26][27] - Retail sales are projected to reach approximately 410 billion HKD in 2026, marking an 8% increase year-on-year, with significant growth expected in jewelry, clothing, and cosmetics [27][28] Real Estate Market Trends - The residential property market is recovering, with the leading index reaching 149.41 points, an 8% increase year-on-year, and the private residential price index showing a 4.9% increase, marking eight consecutive months of growth [28][32] - The "cooling" measures in the property market have been fully implemented, reducing transaction costs and stimulating market liquidity [38][39] Medical Aesthetics Sector - Four Ring Pharmaceutical's medical aesthetics division is becoming a major revenue and profit driver, with a projected revenue of at least 2.5 billion yuan in 2025, reflecting a growth rate exceeding 30% [43][44] - The company has a diverse product matrix, including successful products like "Le Ti Bao" botulinum toxin and "Platinum Hyaluronic Acid," which are contributing significantly to its performance [44][48]

Summary of the Conference Call Industry Overview - The focus is on the medical aesthetics (医美) industry, which is showing signs of demand stabilization and potential growth for the company’s products in 2025 and beyond [1][2]. Key Insights 1. **Demand Stabilization**: Recent surveys in East China indicate a recovery in customer traffic and retail prices after a challenging period from 2022 to 2024, with double-digit growth in customer traffic reported by major institutions [1]. 2. **Retail Price Stability**: Retail prices for established products are stabilizing due to consistent labor and marketing costs, contributing to an upward trend in customer spending [2]. 3. **Upgrading Consumer Behavior**: There is a noticeable trend of existing customers upgrading their consumption, leading to higher average transaction values [2]. Product Segmentation 1. **Injection Fillers**: Hyaluronic acid products face pressure, but the "童颜针" (youthful needle) is expected to see significant growth in 2025 due to more mid-range manufacturers entering the market, with an estimated increase of 15-20% in sales volume [3]. 2. **Collagen Products**: 2025 is projected to be a year of accelerated penetration for collagen products, with an expected factory growth rate of over 20%, although retail prices may face pressure [3]. 3. **Essential Products**: Water-light products remain a necessity, with composite hyaluronic acid products continuing to show resilience, supported by the growth of "童颜水光" and collagen water-light products [3]. 4. **Botulinum Toxin**: This is the second-largest injection category, currently experiencing high single-digit to low double-digit growth in industry sales volume, with growth momentum expected to continue for several years [3]. Company Product Portfolio - Current core products include: - Botulinum toxin "乐提葆" - "斯弗妍" youthful needle - Composite energy product "冷妍" - "铂安润" hyaluronic acid - "黑曜双波" golden microneedle - Future products in development include injectable collagen, silk protein, and PDRN salmon needle [3]. Financial Projections 1. **Profitability Outlook**: The company anticipates a turnaround from loss to profit, estimating a performance of around CNY 200 million in 2025, with a reasonable range between CNY 150 million to CNY 250 million [3]. 2. **Operational Data**: The operational data for various medical aesthetic products is expected to improve, enhancing the reliability of guidance for 2025 and 2027 [3]. 3. **Valuation and Market Potential**: The valuation of the innovative subsidiaries "轩竹" and "惠升" is projected at CNY 4-5 billion, with the generics business expected to generate CNY 1-2 billion in profits. The medical aesthetics segment is projected to achieve CNY 700 million in revenue, warranting a valuation of 25 times [3]. 4. **Future Growth Potential**: The company anticipates a 50% growth potential within the year, with projected profits of CNY 200 million, CNY 790 million, and CNY 900 million for the years 2025, 2026, and 2027 respectively, against a current market capitalization of CNY 12.8 billion, corresponding to PE ratios of 64, 19.7, and 14.2x [3].

Core Viewpoint - Four Seasons Pharmaceutical has launched three self-developed aesthetic products, becoming the only compliant dual regeneration injection holder in China [1] Group 1: Product Launch and Innovation - The newly launched products include: 1) PLLA Youthful Injection, which is divided into two variants based on microsphere particle size: Sifuyan (larger particles for deep injection) and Huiyan Zhen (finer particles for dermal applications) [1] - 2) PCL Tinging, which features uniform particle size and high dispersion to avoid local irritation, enhancing support and viscoelasticity during injection [1] - The company is transitioning from single products to comprehensive aesthetic treatment solutions, addressing the evolving consumer demand for more complete aesthetic plans [1] Group 2: Market Position and Strategy - The core barriers for aesthetic enterprises lie in high-quality pipelines (underlying R&D capabilities) and B2B2C channel management (commercialization capabilities) [2] - Four Seasons Pharmaceutical has built a product matrix of over 60 products through self-research and business development, with its core product, Letibao Botulinum Toxin, covering over 6,200 aesthetic institutions across more than 370 cities in China [2] - The launch of the three regeneration products significantly strengthens the company's pipeline synergy, with expectations for performance growth through collaboration with existing products and mature channel systems [2] Group 3: Financial Performance and Forecast - The company is expected to achieve revenues of 2.32 billion, 3.44 billion, and 4.73 billion yuan in 2025-2027, with growth rates of 22%, 48%, and 37% respectively [2] - The net profit attributable to the parent company is projected to be 60 million, 530 million, and 780 million yuan for the same period, with a corresponding PE of 22 times for 2026 [2] - The adjustment in revenue forecasts reflects the strengthening of pipeline synergy and performance realization from the new aesthetic products [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% within the next six months [19]. Core Viewpoints - The launch of new regenerative products positions the company as the only compliant holder of dual regenerative injectables in China [2]. - The company is transitioning from single product offerings to comprehensive aesthetic treatment solutions, addressing the evolving demands in the aesthetic medicine market [4]. - The company has established a robust product pipeline and distribution network, with over 60 products developed and a presence in more than 6,200 aesthetic institutions across 370 cities [5]. - The traditional pharmaceutical business is stabilizing, with a focus on innovative drugs, including the upcoming launches of key products [6]. Financial Performance and Forecast - Revenue projections for 2025-2027 are adjusted to 2.32 billion, 3.44 billion, and 4.73 billion RMB, respectively, with growth rates of 22%, 48%, and 37% [6]. - The net profit forecast for the same period is 63 million, 528 million, and 783 million RMB, with corresponding growth rates of 129%, 736%, and 48% [6]. - The expected price-to-earnings ratio for 2026 is 22 times, reflecting a positive outlook on profitability [6].